Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 08, 2023 4:05pm EST

Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 07, 2023 7:30am EST

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Nov 01, 2023 7:00am EDT

Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023

Oct 11, 2023 7:30am EDT

Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Sep 28, 2023 7:00am EDT

Matinas BioPharma to Present at Two Investment Conferences in October 2023

Sep 27, 2023 7:00am EDT

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Sep 22, 2023 5:25pm EDT

Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

Sep 06, 2023 7:00am EDT

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

Aug 22, 2023 7:30am EDT

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Aug 09, 2023 4:05pm EDT

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...26
Next
Matinas BioPharma Holdings, Inc.

Science

  • LNC PLATFORM
  • MAT2203
  • MAT2501

Investors

  • COMPANY PROFILE
  • STOCK DATA
  • ANALYST COVERAGE
  • GOVERNANCE
  • PRESS RELEASES
  • EVENTS
  • PRESENTATIONS
  • SEC FILINGS

Company

  • OVERVIEW
  • OUR TEAM
  • NEWS
  • CAREERS
  • CONTACT US

Register for updates

Follow Us

LinkedIn facebook twitter
© 2023 Matinas BioPharma Holdings, Inc. All Rights Reserved.